NCT02019719View on ClinicalTrials.gov

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

August 6, 2014

Study Completion Date

August 6, 2014

Conditions
Anaemia
Interventions
DRUG

GSK1278863

GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.

DRUG

Placebo

Film coated tablets of GSK1278863 matching placebo for oral administration.

Trial Locations (21)

446-0053

GSK Investigational Site, Aichi

446-0065

GSK Investigational Site, Aichi

454-0932

GSK Investigational Site, Aichi

455-0021

GSK Investigational Site, Aichi

465-0025

GSK Investigational Site, Aichi

470-1201

GSK Investigational Site, Aichi

276-0031

GSK Investigational Site, Chiba

804-0094

GSK Investigational Site, Fukuoka

300-0835

GSK Investigational Site, Ibaraki

305-0861

GSK Investigational Site, Ibaraki

310-0844

GSK Investigational Site, Ibaraki

761-8024

GSK Investigational Site, Kagawa

216-0007

GSK Investigational Site, Kanagawa

981-0911

GSK Investigational Site, Miyagi

390-0821

GSK Investigational Site, Nagano

390-1401

GSK Investigational Site, Nagano

950-2038

GSK Investigational Site, Niigata

543-0052

GSK Investigational Site, Osaka

547-0024

GSK Investigational Site, Osaka

158-0094

GSK Investigational Site, Tokyo

930-0964

GSK Investigational Site, Toyama

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02019719 - Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter